As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.
You may also be interested in...
BeiGene CEO John Oyler On Investing In Biotech In China: An Interview With PharmAsia News (Part 2 of 2)
BeiGene CEO John Oyler discusses what is missing in China’s venture capital environment if it truly wants to foster innovation. Based in Beijing, BeiGene’s lead product entered the clinic in 2013.
BeiGene CEO John Oyler On Investing In Biotech In China: An Interview With PharmAsia News (Part 1 Of 2)
BeiGene CEO John Oyler discusses what is missing in China’s venture capital environment if it truly wants to foster innovation. Based in Beijing, BeiGene’s lead product entered the clinic in 2013.
China Innovation Takes Another Step: Merck KGAA Ties Up With BeiGene On Global Agreement For BRAF Inhibitor
In a win for China’s innovation strategy, leading local player BeiGene partners its second-generation BRAF inhibitor, which may have opportunities beyond metastatic melanoma where Roche has made its mark with BRAF inhibitor Zelboraf.